DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype
- 4 January 2019
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 475 (1) , 49-58
Abstract
Intrahepatic cholangiocarcinoma is a complex disease with three different histologic subtypes, the large duct, small duct, and bile ductular types. In the present study, we elucidated whether the three histological subtypes have differences in their methylation profiles and developed a DNA methylation marker that might help identify a subset of ICC with a different prognosis. We screened 113 promoter CpG island loci against 10 cases of intrahepatic cholangiocarcinoma and normal cystic ducts using the MethyLight assay and selected 30 CpG island loci with cancer-associated hypermethylation. Then, we analyzed 172 intrahepatic cholangiocarcinomas for the methylation state at these 30 loci. Six loci, including DLEC1, were more frequently methylated in the bile ductular type and small duct type, whereas six loci were more frequently methylated in the large duct type. Of these 30 loci, DLEC1 methylation was found mainly in the bile ductular type and small duct type but rarely in the large duct type. DLEC1 methylation was significantly associated with a better clinical outcome in intrahepatic cholangiocarcinomas of the small duct type but not of the bile ductular type. DLEC1 methylation was an independent prognostic variable in both cancer-specific survival and recurrence-free survival. For patients with intrahepatic cholangiocarcinoma of the small duct type (n = 68), DLEC1 methylation was found in 26 (38.2%) and was associated with a better clinical outcome for both cancer-specific survival and recurrence-free survival. Our findings suggest that DLEC1 methylation can be utilized to identify a subset with a better prognosis in intrahepatic cholangiocarcinomas of the small duct type.Keywords
Funding Information
- National Research Foundation (NRF) funded by the Korean Ministry of Science, ICT and Future Planning (2016M3A9B6026921)
- Korea Health Industry Development Institute (HI14C1277)
- Seoul National University Hospital (0320170070 (2017-1176))
- Seoul National University (0431-20170012)
This publication has 35 references indexed in Scilit:
- Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneityWorld Journal of Gastrointestinal Oncology, 2012
- Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expressionLaboratory Investigation, 2011
- Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancerLaboratory Investigation, 2011
- Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patientsOncology Letters, 2010
- Prognostic Implications of and Relationship Between CpG Island Hypermethylation and Repetitive DNA Hypomethylation in Hepatocellular CarcinomaClinical Cancer Research, 2009
- Prognostic molecular markers in cholangiocarcinoma: A systematic reviewEuropean Journal of Cancer, 2008
- The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycleJournal of Hepatology, 2008
- Epigenetic Inactivation of a Cluster of Genes Flanking MLH1 in Microsatellite-Unstable Colorectal CancerCancer Research, 2007
- Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomasOncogene, 2004
- Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?Journal of Hepatology, 2004